HISTOGEN INC - HSTO STOCK NEWS

Histogen Inc. (HSTO) reported significant financial developments, securing $25.3 million from financings and warrant exercises. The Phase 1 study of emricasan for COVID-19 is expected to start in Q1 2021, while the HST 003 trial for knee cartilage regeneration is anticipated in Q2 2021. The company appointed Dr. Susan Windham-Bannister to its board, enhancing its leadership. However, Q4 2020 revenues dropped to $0.5 million from $1.6 million in Q4 2019, largely due to reduced supply orders. Furthermore, R&D expenses increased by $0.5 million, reflecting ongoing developments.

Histogen Inc. (NASDAQ: HSTO) has welcomed Dr. Susan R. Windham-Bannister to its Board of Directors, aiming to leverage her extensive industry experience for strategic growth. Dr. Windham-Bannister, a recognized leader in market access and optimization, has previously held significant roles in major life sciences organizations, enhancing business strategies and launching therapeutics. This appointment comes as Histogen focuses on advancing its clinical-stage product pipeline and improving shareholder value. The company continues to develop innovative restorative therapeutics targeting various medical needs.

Histogen Inc. (NASDAQ: HSTO) is set to release its financial results for the fourth quarter and the year ended December 31, 2020, on March 11, 2021, after market close. The company is focused on developing first-in-class restorative therapeutics that leverage the body’s natural repair processes. Histogen’s technology platform utilizes cell conditioned media and extracellular matrix materials from hypoxia-induced multipotent cells, targeting various therapeutic areas, including hair growth and joint regeneration.

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, announced its participation in the H.C. Wainwright Global Life Sciences Virtual Conference. The presentation will be available for on-demand listening starting March 9, 2021, at 7:00 AM Eastern Time. Histogen focuses on developing innovative restorative therapeutics that harness the body's natural repair mechanisms. Their technology platform features cell conditioned media and extracellular matrix materials for various therapeutic applications, including hair growth and joint regeneration.

Histogen Inc. (NASDAQ: HSTO) announced positive week 26 results from its Phase 1b/2a clinical trial of HST-001 for androgenic alopecia. Patients showed statistically significant changes in hair count, with 84% of subjects responding positively to the treatment. Importantly, HST-001 was found to be safe and well tolerated, with no serious adverse events reported. Histogen is now planning a more substantive clinical trial in the second half of 2021 to further evaluate HST-001's efficacy and clinical pathway for registration trials.

Histogen Inc. (NASDAQ: HSTO) announced that the FDA has verbally notified the company of additional questions regarding its IND application for the Phase 1/2 trial of HST-003, aimed at evaluating safety and efficacy in knee cartilage regeneration. The FDA indicated a clinical hold related to pending CMC information, and a written notice is expected by February 12, 2021. Histogen is committed to addressing the FDA's concerns to facilitate the trial's progression.

Histogen, Inc. (NASDAQ: HSTO) announced a public offering of 11,600,000 shares of common stock, pre-funded warrants for 2,400,000 shares, and warrants for 14,000,000 shares, priced at $1.00 each. This upsized offering aims to raise $14 million to enhance its research and development efforts for innovative therapies that support biological function. DLA Piper represented Histogen in this transaction, highlighting their expertise in the life sciences sector.

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, announced its participation in the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. The presentation will be available for on-demand listening starting January 11, 2021, at 6:00 a.m. Eastern Time on the Investors section of the Histogen website. Histogen focuses on developing innovative restorative therapeutics using hypoxia-induced multipotent cells, targeting applications for hair growth, dermal rejuvenation, joint cartilage regeneration, and spinal disk repair.

Histogen Inc. (Nasdaq: HSTO) announced the closing of a public offering of 11.6 million shares of common stock, including pre-funded warrants to purchase up to 2.4 million shares, raising approximately $14 million. The offering price was $1.00 per share, with common warrants and pre-funded warrants priced at $1.00 and $0.0001, respectively. The proceeds will support working capital and development of therapeutic programs. H.C. Wainwright & Co. acted as the placement agent for this offering, which was registered with the SEC.